Mohammad Hassan Eftekhari; Maryam Ranjbar Zahedani; Atefeh Kohansal
Abstract
Background: Normal Body Mass Index (BMI) = 18.5-24.9 kg/m2 and high Body Fat (BF), have been defined as Normal Weigh Obesity (NWO), which can increase the risk of Metabolic Syndrome (MetS) and cardiovascular diseases. The present study aimed to determine the association between NWO and MetS indicators, ...
Read More
Background: Normal Body Mass Index (BMI) = 18.5-24.9 kg/m2 and high Body Fat (BF), have been defined as Normal Weigh Obesity (NWO), which can increase the risk of Metabolic Syndrome (MetS) and cardiovascular diseases. The present study aimed to determine the association between NWO and MetS indicators, Insulin Resistance (IR), and inflammatory and oxidative stress indices in NW obese compared to normal weight women referring to Imam Reza medical center, Shiraz, Iran. Methods: In this case-control study, 41 healthy NW obese Iranian women were recruited and compared to 45 healthy non-obese control subjects. Anthropometric features, body composition, blood pressure, inflammation and oxidative stress indices, fasting insulin, lipid profile, and blood sugar were measured. IR was also assessed by means of special formulas. Results: The results showed a significant difference between the NWO and the control group regarding anthropometric measurements and body composition, including waist (p=0.008) and hip (p<0.001) circumferences, BF (p<0.001), skeletal muscle (p=0.03), protein(p=0.04), body cell mass(p=0.02), bone mass content(p=0.04), and arm circumference(p<0.001). All subjects had normal systolic and diastolic blood pressures. However, the NWO group showed significantly higher serum concentrations of triglycerides (p=0.02), total cholesterol(p=0.02), and C-reactive protein (p<0.001). On the other hand, the results of McAuley test indicated significantly lower insulin sensitivity in the NWO group (p=0.03). Besides, serum MDA concentration did not have a marked differences in both study groups. Conclusion:
Zohreh Mazloom; Mohammad Hossein Dabbaghmanesh; Mahsa Moazen; Sara Bagheri
Volume 3, Issue 4 , October 2015, , Pages 146-152
Abstract
Background: Use of glucosamine as an alternative treatment for osteoarthritis is becoming more frequent, including in those who have diabetes at the same time. The results from in vitro and animal studies propose that glucosamine may inversely affect glucose metabolism. However, the recommended dose ...
Read More
Background: Use of glucosamine as an alternative treatment for osteoarthritis is becoming more frequent, including in those who have diabetes at the same time. The results from in vitro and animal studies propose that glucosamine may inversely affect glucose metabolism. However, the recommended dose of oral glucosamine in healthy people or diabetics did not have such effects consistently. The aim of the present study was to assess the effect of glucosamine on glycemic control and insulin resistance in type 2 diabetic patients. Methods: Fifty-four patients with type 2 diabetes participated in this randomized, double-blind, placebo-controlled study. The participants were assigned to receive 1500 mg glucosamine hydrochloride or placebo for 12 weeks. After determining their baseline characteristics, body mass index and dietary intake components, fasting blood glucose and fasting insulin were measured at weeks of 0, 8, and 12. Indices of insulin function including quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated by specific formulas. Independent t-test and general linear model repeated measures were used to analyze the data. Results: In the glucosamine group, the means of fasting blood glucose and insulin were 107.31±24.07 mg/dl and 8.75±4.37 μu/ ml, respectively at baseline, which reached 112.38±31.50 and 9.10±4.17 at week 12. In the placebo group, the mean for fasting blood glucose and insulin were 103.84±24.15 and 9.79±4.02 at the beginning of the study, which reached to 111.40±26.43 and 8.58±3.68 at week 12. The results showed that there were no significant differences in fasting blood glucose, insulin, HOMA-IR and QUICKI indices at all the studied time points (weeks of 0, 8 and 12) within or between the groups. Conclusion: Twelve weeks of a normal recommended dose of glucosamine supplements may not have adverse effects on glycemic control and insulin resistance in type 2 diabetic patients.Trial registration number: IRCT2014031811785N2.
Zohreh Mazloom; Seyedeh Maryam Abdollahzadeh; Mohammad Hossein Dabbaghmanesh; Abbas Rezaianzadeh
Volume 2, Issue 1 , January 2014, , Pages 8-14
Abstract
Background: Diabetes Mellitus (DM) is closely associated with reduction of antioxidant defense system. In the present study, we investigated the antioxidant effect of quercetin supplementation on the glycemic control, lipid profile and oxidative stress indices in patients with type 2diabetes. Methods: ...
Read More
Background: Diabetes Mellitus (DM) is closely associated with reduction of antioxidant defense system. In the present study, we investigated the antioxidant effect of quercetin supplementation on the glycemic control, lipid profile and oxidative stress indices in patients with type 2diabetes. Methods: Forty seven patients with type 2 diabetes, aged 30-60 years old, were randomly assigned to supplement their daily diet with either an oral quercetin (250 mg/d) or identical placebo (cellulose) capsules for 8 weeks. The supplements were provided to the patients biweekly. Anthropometric data as well as glycemic indices, lipid profile and oxidative stress parameters of blood samples were determined at the baseline and endpoint of the study. Results: Dietary quercetin supplementation significantly improved the total antioxidant capacity (TAC) in the intervention group, when compared to the placebo group (P=0.043). It also resulted in a statistically significant reduction in serum concentration of atherogenic oxidized LDL (ox-LDL) (P0.05). Conclusions: Oral quercetin supplementation was beneficial in improving the antioxidant status of patients with type 2 diabetes while having no other significant effect on glycemic control and lipid profile; however, conducting further studies, using different doses, on the glycemiccontrol and/or hyperlipidemia of thepopulation seems to be valuable. Trial Registration Number: IRCT2012101911168N